IFN-γ treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner

Journal of Interferon and Cytokine Research

Volumn 30, Issue 6, 2010, Pages 439-449

  Weiss, Ido D ^a   Wald, Ori ^a   Wald, Hanna ^a   Beider, Katia ^a   Abraham, Michal ^a   Galun, Eithan ^a   Nagler, Arnon ^b   Peled, Amnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL FUNCTION; CELL INFILTRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG MECHANISM; FEMALE; INFLUENZA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL COUNT; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; HEMAGGLUTINATION TESTS; IMMUNOPHENOTYPING; INFLUENZA A VIRUS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LUNG; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; SPLEEN; T-LYMPHOCYTES; VIRAL LOAD;

MUS; ORTHOMYXOVIRIDAE;

EID: 77953546692     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2009.0084     Document Type: Article

References (36)

1. Baumgarth N, Kelso A. 1996. In vivo blockade of gamma interferon affects the infl uenza virus-induced humoral and the local cellular immune response in lung tissue. J Virol 70 ( 7 ): 4411-4418.
2. Beilharz MW, Cummins JM, Bennett AL. 2007. Protection from lethal infl uenza virus challenge by oral type 1 interferon. Biochem Biophys Res Commun 355 ( 3 ): 740-744.
3. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17: 189-220.
4. Biron CA, Sonnenfeld G, Welsh RM. 1984. Interferon induces natural killer cell blastogenesis in vivo. J Leukoc Biol 35 ( 1 ): 31-37.
5. Biron CA, Young HA, Kasaian MT. 1990. Interleukin 2-induced proliferation of murine natural killer cells in vivo. J Exp Med 171 ( 1 ): 173-188.
6. Coro ES, Chang WL, Baumgarth N. 2006. Type I IFN receptor signals directly stimulate local B cells early following infl uenza virus infection. J Immunol 176 ( 7 ): 4343-4351.
7. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. 2006. Fatal outcome of human infl uenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12 ( 10 ): 1203-1207.
8. De Maria A, Fogli M, Mazza S, Basso M, Picciotto A, Costa P, Congia S, Mingari MC, Moretta L. 2007. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 37 ( 2 ): 445-455.
9. Fehniger TA, Caligiuri MA. 2001. Interleukin 15: biology and relevance to human disease. Blood 97 ( 1 ): 14-32.
10. Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC. 1998. Virus-specifi c CD8+ T cells in primary and secondary infl uenza pneumonia. Immunity 8 ( 6 ): 683-691.
11. Garcia-Sastre A. 2001. Inhibition of interferon-mediated antiviral responses by infl uenza A viruses and other negative-strand RNA viruses. Virology 279 ( 2 ): 375-384.
12. Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, Hanna J, Qimron U, Landau G, Greenbaum E, Zakay-Rones Z, Porgador A, Mandelboim O. 2006. Lethal infl uenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 7 ( 5 ): 517-523.
13. Hierholzer JC, Suggs MT, Hall EC. 1969. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl Microbiol 18 ( 5 ): 824-833.
14. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 ( 5685 ): 872-874.
15. Kinoshita M, Kuranaga N, Matsumoto A, Ono S, Shinomiya N, Hiraide H, Seki S. 2006. Multiple interleukin-18 injections promote both mouse Th1 and Th2 responses after sublethal Escherichia coli infection. Clin Exp Immunol 143 ( 1 ): 41-49.
16. Koka R, Burkett PR, Chien M, Chai S, Chan F, Lodolce JP, Boone DL, Ma A. 2003. Interleukin (IL)-15R[alpha]-defi cient natural killer cells survive in normal but not IL-15R[alpha]-defi cient mice. J Exp Med 197 ( 8 ): 977-984.
17. Lee SH, Miyagi T, Biron CA. 2007. Keeping NK cells in highly regulated antiviral warfare. Trends Immunol 28 ( 6 ): 252-259.
18. Lidstrom C, Matthiesen L, Berg G, Sharma S, Ernerudh J, Ekerfelt C. 2003. Cytokine secretion patterns of NK cells and macrophages in early human pregnancy decidua and blood: implications for suppressor macrophages in decidua. Am J Reprod Immunol 50 ( 6 ): 444-452.
19. Maruyama T, Watanabe K, Takei I, Kasuga A, Shimada A, Yanagawa T, Kasatani T, Suzuki Y, Kataoka KS. 1991. Anti-asialo GM1 antibody suppression of cyclophosphamide-induced diabetes in NOD mice. Diabetes Res 17 ( 1 ): 37-41.
20. Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL. 1996. Interleukin-4 causes delayed virus clearance in infl uenza virusinfected mice. J Virol 70 ( 8 ): 5230-5235. (Pubitemid 26240695)
21. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. 2008. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 15 ( 2 ): 226-233.
22. Morris SC, Orekhova T, Meadows MJ, Heidorn SM, Yang J, Finkelman FD. 2006. IL-4 induces in vivo production of IFNgamma by NK and NKT cells. J Immunol 176 ( 9 ): 5299-5305.
23. Neff-LaFord HD, Vorderstrasse BA, Lawrence BP. 2003. Fewer CTL, not enhanced NK cells, are suffi cient for viral clearance from the lungs of immunocompromised mice. Cell Immunol 226 ( 1 ): 54-64.
24. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, Caligiuri MA, Durbin JE, Biron CA. 2002. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169 ( 8 ): 4279-4287.
25. Orange JS. 2002. Human natural killer cell defi ciencies and susceptibility to infection. Microbes Infect 4 ( 15 ): 1545-1558.
26. Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW. 2003. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 9 ( 1 ): 76-83.
27. Rainsford KD. 2006. Infl uenza ("Bird Flu"), infl ammation and antiinfl ammatory/analgesic drugs. Infl ammopharmacology 14 ( 1-2 ): 2-9.
28. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Muller W, Di Santo JP. 2003. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 101 ( 12 ): 4887-4893. (Pubitemid 36857750)
29. Stein-Streilein J, Guffee J. 1986. In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary infl uenza infection. J Immunol 136 ( 4 ): 1435-1441.
30. Sun J, Madan R, Karp CL, Braciale TJ. 2009. Effector T cells control lung infl ammation during acute infl uenza virus infection by producing IL-10. Nat Med 15 ( 3 ): 277-284.
31. Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW. 2006. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol 80 ( 9 ): 4286-4291.
32. Tamura S, Kurata T. 2004. Defense mechanisms against infl uenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57 ( 6 ): 236-247.
33. Wald O, Weiss ID, Wald H, Shoham H, Bar-Shavit Y, Beider K, Galun E, Weiss L, Flaishon L, Shachar I, Nagler A, Lu B, Gerard C, Gao JL, Mishani E, Farber J, Peled A. 2006. IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 176 ( 8 ): 4716-4729.
34. Wang J, Xu J, Zhang W, Wei H, Tian Z. 2005. TLR3 ligand-induced accumulation of activated splenic natural killer cells into liver. Cell Mol Immunol 2 ( 6 ): 449-453.
35. Wuest T, Austin BA, Uematsu S, Thapa M, Akira S, Carr DJ. 2006. Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10. J Neuroimmunol 179 ( 1-2 ): 46-52.
36. Zhang J, Sun R, Wei H, Wu D, Tian Z. 2007. Toll-like receptor 3 agonist enhances IFN-gamma and TNF-alpha production by murine uterine NK cells. Int Immunopharmacol 7 ( 5 ): 588-596.